46-0469-42

antibody from Invitrogen Antibodies

Targeting: CD46 MCP, MGC26544, MIC10, TLX, TRA2.10

Provider product page for 46-0469-42

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [4]
Comments [0]
Validations
Flow cytometry [1]
Other assay [3]

Submit

Product number: 46-0469-42 - Provider product page
Provider: Invitrogen Antibodies
Product name: CD46 Monoclonal Antibody (8E2), PerCP-eFluor™ 710, eBioscience™
Antibody type: Monoclonal
Antigen: Other
Description: Description: The 8E2 monoclonal antibody reacts with human CD46 (membrane cofactor protein). CD46 is a transmembrane glycoprotein consisting of four regularly expressed isoforms, giving an electrophoretic profile of two heterogeneous protein species of 51-58 kDa ("lower band") and 59-68 kDa ("upper band"). CD46 is expressed on the majority of nucleated cells, and functions as a regulator of complement function by binding complement components C3b and C4b, which serves to protect the host from autologous complement attack. CD46 has been called a "pathogen magnet" as it is known to play a role in the entry of several pathogens including strains of measles virus, human herpes virus type 6, group A streptococci and Neisseria.
Antibody clone number: 8E2
Concentration: 5 µL/Test

CD46 protein structure - 46-0469-42 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 Major adenovirus receptor expression levels on BC cell lines. Cells were stained with antibodies against coxsackievirus and adenovirus receptor (CAR) ( A ), cluster of differentiation 46 (CD46) ( B ), desmoglein-2 receptor (DSG-2) ( C ), and integrins alphavbeta3 and alphavbeta5 ( D,E ). Receptor expression was measured via flow cytometry, expressed as percentage of CAR, CD46, DSG-2, and integrin-receptor-positive cells. Hela cells were used as positive control. Unlabeled cells (negative controls) were used to set the background gate below 1%. A total of 10,000 viable cells were counted.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 CD46 co-stimulation provides superior support for CTL activity. a CD46 expression on the surface of resting human CD4 + and CD8 + T cells assessed by FACS analysis ( n = 4, gating strategy in Supplementary Fig. 7a ). b Comparison of IFN-gamma, TNF-alpha and IL-10 secretion by CD3 + CD46-activated T cells. Purified CD4 + and CD8 + T cells from healthy donors were left non-activated (NA) or stimulated with immobilized antibodies to CD3, CD3 + CD28 or CD3 + CD46 and cytokines measured 60 h post activation ( n = 5). c, d Degranulation (CD107a staining, ( c )) and granzyme B expression ( d ) by CD8 + T cells upon CD46 co-stimulation. CD8 + T cells were stimulated as in ( a ) and CD107a and granzyme B expression assessed with left panels showing representative cytometry images and right panels corresponding quantifications ( n = 3, gating strategy in Supplementary Fig. 7b ). e Killing activity of CD46-activated CD8 + T cells. T cells were stimulated as depicted for 24 h and cytotoxic activity of differently activated CD8 + T cells towards DU145 target cells assessed 24 h post co-culture of T cells and DU145 cells ( n = 4, gating strategy in Supplementary Fig. 7c ). f Effect of CD46 co-stimulation on CD8 + T-cell proliferation. Purified T cells were activated as indicated for 5 days and cell proliferation measured each day ( n = 4) (black circles, non-activated cells; green, blue, and red circles, CD3, CD3 + CD28 or CD3 + CD46-activated cells, res

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 NF-kappaB-independent role of T6BP and NDP52 in MeV replication. ( A ) p65/RelA-expressing HeLa cells and shControl-expressing HeLa cells were transfected with the indicated siRNAs for 48 h, then lysed, and the expression of relevant proteins was probed by Western blot; ( B ) p65/RelA-expressing HeLa cells and shControl-expressing cells were infected with MeV (MOI 0.1). 48 h post infection, infectious virus particles were titrated by a plaque assay; ( C ) Cells from ( B ) were lysed 48 h post infection. Expression of measles virus N and P proteins were assessed by Western blotting. Representative results from shp65#1 are shown and are accompanied by a graph representing the intensity of MeV-N and MeV-P expression over Actin normalized to shControl-expressing cells condition. Means +- SD of four independent experiments are represented (two with the shp65#1 cell line and two with the shp65#2 cell line); ( D ) p65/RelA-expressing HeLa cells and shControl-expressing HeLa cells were stained for CD46 expression and analyzed by flow cytometry; grey histograms = isotype control, white histograms = CD46 labelling. ( E - G ) p65/RelA-expressing HeLa cells were treated with indicated siRNAs for 48 h; ( E ) Cells were lysed and the expression of relevant proteins was probed by Western blotting. Results regarding cell line shp65 #1 are represented. Similar results were obtained with shp65 #2. Cells were infected with MeV (MOI 0.1) and 48 h post infection, infectious virus part